These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15199528)

  • 1. Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial.
    Pelegrí A; Calvo L; Mayordomo JI; Florián J; Vázquez S; Arcusa A; Martn-Richard M; Bayo JL; Virizuela J; Carrasco E; Antón A;
    Semin Oncol; 2004 Apr; 31(2 Suppl 5):20-4. PubMed ID: 15199528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial.
    Pelegrí A; Calvo L; Antón A; Mayordomo JI; Florián J; Vásquez S; Arcusa A; Martín-Richard M; Bayo JL; Carrasco E; Virizuela J;
    Clin Breast Cancer; 2005 Dec; 6(5):433-8. PubMed ID: 16381627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
    Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
    Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
    Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
    Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
    Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
    Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
    Laufman LR; Spiridonidis CH; Pritchard J; Roach R; Zangmeister J; Larrimer N; Moore T; Segal M; Jones J; Patel T; Gutterman L; Carman L; Colborn D; Kuebler JP
    Ann Oncol; 2001 Sep; 12(9):1259-64. PubMed ID: 11697837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
    Schmid P; Krocker J; Jehn C; Michniewicz K; Lehenbauer-Dehm S; Eggemann H; Heilmann V; Kümmel S; Schulz CO; Dieing A; Wischnewsky MB; Hauptmann S; Elling D; Possinger K; Flath B
    Ann Oncol; 2005 Oct; 16(10):1624-31. PubMed ID: 16030028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer.
    Alexopoulos A; Tryfonopoulos D; Karamouzis MV; Gerasimidis G; Karydas I; Kandilis K; Stavrakakis J; Stavrinides H; Georganta C; Ardavanis A; Rigatos G
    Ann Oncol; 2004 Jan; 15(1):95-9. PubMed ID: 14679126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
    Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
    Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
    Brugnatelli S; Danova M; De Bella MT; Vaglica M; Manuguerra G; Riccardi A; Palmeri S
    Oncology; 2002; 62(1):33-8. PubMed ID: 11810041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
    O'Shaughnessy JA; Pluenneke R; Sternberg J; Khandelwal P; Ilegbodu D; Asmar L
    Clin Breast Cancer; 2006 Feb; 6(6):505-10. PubMed ID: 16595033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
    Murialdo R; Bertolotti F; Pastorino G; Mencoboni M; Bergaglio M; Folco U; Cinzia N; Vaira F; Simoni C; Canobbio L; Parodi M; Brema F; Ballestrero A
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1009-16. PubMed ID: 21327683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
    Casal J; Amenedo M; Mel JR; Antón LM; Rodríguez-López R; López-López R; González-Ageitos A; Castellanos J; Constenla M; Tisaire JL
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):725-32. PubMed ID: 17273825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
    Hensley ML; Maki R; Venkatraman E; Geller G; Lovegren M; Aghajanian C; Sabbatini P; Tong W; Barakat R; Spriggs DR
    J Clin Oncol; 2002 Jun; 20(12):2824-31. PubMed ID: 12065559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial.
    Schneeweiss A; Schuetz F; Rudlowski C; Hahn M; Lauschner I; Sinn HP; von Fournier D; Sohn C
    Anticancer Drugs; 2005 Oct; 16(9):1023-8. PubMed ID: 16162980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
    Mavroudis D; Malamos N; Polyzos A; Kouroussis Ch; Christophilakis Ch; Varthalitis I; Androulakis N; Kalbakis K; Milaki G; Georgoulias V;
    Oncology; 2004; 67(3-4):250-6. PubMed ID: 15557786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
    Kontopodis E; Kentepozidis N; Christophyllakis Ch; Boukovinas I; Kalykaki A; Kalbakis K; Vamvakas L; Agelaki S; Kotsakis A; Vardakis N; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):153-60. PubMed ID: 25398698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
    Neri B; Vannini L; Giordano C; Grifoni R; Pantaleo P; Baldazzi V; Crisci A; Lapini A; Raugei A; Carini M
    Anticancer Drugs; 2007 Nov; 18(10):1207-11. PubMed ID: 17893522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial.
    Colomer R; Llombart A; Lluch A; Ojeda B; Barnadas A; Carañana V; Fernández Y; De Paz L; Guillem V; Alonso S
    Semin Oncol; 2000 Feb; 27(1 Suppl 2):20-4. PubMed ID: 10697032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.